Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00134485
Registration number
NCT00134485
Ethics application status
Date submitted
22/08/2005
Date registered
24/08/2005
Date last updated
30/10/2007
Titles & IDs
Public title
Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia
Query!
Scientific title
Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia
Query!
Secondary ID [1]
0
0
A5091026
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hypercholesterolemia, Familial
0
0
Query!
Hyperlipidemia
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Other metabolic disorders
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - torcetrapib/atorvastatin
Treatment: Drugs - atorvastatin
Treatment: Drugs: torcetrapib/atorvastatin
Treatment: Drugs: atorvastatin
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change in HDL-C and LDL-C
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Secondary outcome [1]
0
0
Changes in other lipid parameters
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Eligibility
Key inclusion criteria
- Diagnosis of Heterozygous Familial Hypercholesterolemia
- At least 18 years of age
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor)
therapy other than atorvastatin or other concomitant therapy with known lipid altering
effects on LDL-C and HDL-C including fibrates and nicotinic acid (high doses)
- Subjects taking any drugs known to be associated with an increased risk of myositis in
combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could affect
subject safety, preclude evaluation of response, or render unlikely that the subject
would complete the study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Pfizer Investigational Site - Camperdown
Query!
Recruitment hospital [2]
0
0
Pfizer Investigational Site - Woolloongabba
Query!
Recruitment hospital [3]
0
0
Pfizer Investigational Site - North Adelaide
Query!
Recruitment hospital [4]
0
0
Pfizer Investigational Site - Clayton
Query!
Recruitment hospital [5]
0
0
Pfizer Investigational Site - Perth
Query!
Recruitment hospital [6]
0
0
Pfizer Investigational Site - Darlinghurst
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [3]
0
0
5006 - North Adelaide
Query!
Recruitment postcode(s) [4]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [5]
0
0
6000 - Perth
Query!
Recruitment postcode(s) [6]
0
0
NSW 2010 - Darlinghurst
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
District of Columbia
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Hawaii
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Iowa
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maine
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Texas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Wisconsin
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
Quebec
Query!
Country [14]
0
0
Denmark
Query!
State/province [14]
0
0
Aalborg
Query!
Country [15]
0
0
Denmark
Query!
State/province [15]
0
0
Arhus C
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Dijon
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Nantes cedex 01
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Paris
Query!
Country [19]
0
0
Iceland
Query!
State/province [19]
0
0
Kopavogur
Query!
Country [20]
0
0
Norway
Query!
State/province [20]
0
0
Oslo
Query!
Country [21]
0
0
South Africa
Query!
State/province [21]
0
0
Cape Town
Query!
Country [22]
0
0
South Africa
Query!
State/province [22]
0
0
Western Cape
Query!
Country [23]
0
0
South Africa
Query!
State/province [23]
0
0
Bloemfontein
Query!
Country [24]
0
0
Sweden
Query!
State/province [24]
0
0
Goteborg
Query!
Country [25]
0
0
Sweden
Query!
State/province [25]
0
0
Linkoping
Query!
Country [26]
0
0
Sweden
Query!
State/province [26]
0
0
Malmo
Query!
Country [27]
0
0
Sweden
Query!
State/province [27]
0
0
Stockholm
Query!
Country [28]
0
0
Query!
State/province [28]
0
0
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To evaluate the efficacy and safety of torcetrapib/atorvastatin compared to atorvastatin
alone in patients with heterozygous familial hypercholesterolemia
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00134485
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00134485
Download to PDF